Results 21 to 30 of about 46,843 (269)
Significant elevation of free itraconazole concentration at onset of adverse effects: A case report
Clinical Case Reports, 2021 Free itraconazole and hydroxyitraconazole concentrations were markedly elevated despite almost no changes in total concentrations when itraconazole was discontinued due to adverse effects.
Ryota Tanaka +10 more
doaj +1 more source
Effect of itraconazole on the cornea in a murine suture model and penetrating keratoplasty model [PDF]
International Journal of Ophthalmology, 2017 AIM: To investigate the anti-(lymph)angiogenic and/or anti-inflammatory effect of itraconazole in a corneal suture model and penetrating keratoplasty (PK) model.
Yang Kyung Cho +3 more
doaj +1 more source
The place for itraconazole in treatment [PDF]
Journal of Antimicrobial Chemotherapy, 2005 The incidence of systemic fungal infections has risen sharply in the last two decades, reflecting a rise in the number of patients who are predisposed to these diseases because they are immunosuppressed or immunocompromised. The growing use of intensive chemotherapy to treat cancer, highly immunosuppressive drug regimens (not only in transplant ...
Johan Maertens, Marc Boogaerts
openaire +3 more sources
CAQ Corner: Basic concepts of transplant immunology
, 2022 Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley +1 more source
Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B
Molecules, 2022 Gilteritinib, an FDA-approved tyrosine kinase inhibitor approved for the treatment of relapsed/refractory FLT3-mutated acute myeloid leukemia, is primarily eliminated via CYP3A4-mediated metabolism, a pathway that is sensitive to the co-administration of
Dominique A. Garrison +6 more
doaj +1 more source
Clinical Cancer Research, 2020 Purpose: Itraconazole has been repurposed as an anticancer therapeutic agent for multiple malignancies. In preclinical models, itraconazole has antiangiogenic properties and inhibits Hedgehog pathway activity.
D. Gerber +23 more
semanticscholar +1 more source
PLoS ONE, 2020 BackgroundChronic pulmonary aspergillosis (CPA) requires prolonged treatment with itraconazole or voriconazole. However, adverse events (AEs) are common with the use of these agents, with the need to discontinue the offending drug in a significant ...
Ronald Olum +4 more
doaj +1 more source
Combining derivative and synchronous approaches for simultaneous spectrofluorimetric determination of terbinafine and itraconazole [PDF]
Royal Society Open Science, 2020 In this study, determination of terbinafine and itraconazole down to biological concentration level has been carried out. The determination is based on increasing the selectivity of the spectrofluorimetric technique by combining both derivative and ...
Heba Elmansi +3 more
doaj +1 more source
Treatment of onychomycosis with itraconazole
Journal of Dermatological Treatment, 1992 A group of 23 patients with dermatophyte or Candida infections of fingernails or toenails were treated with itraconazole 100 mg daily in an open-label study. Treatment was continued for up to 4 months for fingernails and up to 6 months for toenails. At the end of the treatment, 12 patients were cured and eight were not. The response rate for fingernail
Rongioletti F. +3 more
openaire +4 more sources
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
New England Journal of Medicine, 2007 BACKGROUND Patients with neutropenia resulting from chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome are at high risk for difficult-to-treat and often fatal invasive fungal infections.
O. Cornely +13 more
semanticscholar +1 more source